ea0098t6 | Trials In Progress | NANETS2023
Halfdanarson Thorvardur R.
, Capdevila Jaume
, Halperin Daniel M.
, Herrmann Ken
, Kong Grace
, Mailman Josh
, Reidy-Lagunes Diane
, Srirajaskanthan Raj
, Sierras Cristina
, Rotger Amanda
Background: Targeted radionuclide therapies (TRTs) have changed the treatment paradigm of neuroendocrine tumors (NET) and are expected to be widely available for patients with various gastroenteropancreatic (GEP)-NET phenotypes. However, while they have great potential, TRT-based therapeutic strategies for high-grade GEP-NET demonstrate variable outcomes, and there is a current lack of tools to identify patients who are likely to respond to TRT. To address this need, the rando...